Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.

Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: Compounds of the formula W, Q, R1, R2 and R10 are as defined in the specification. A process for their preparation and pharmaceutical compositions and methods of treatment involving their use in the treatment of respiratory disease including, for example, asthma, are also provided.

Abstract: Process for preparing 5-substituted pyrrolo [3,4-d] pyrimidine-2-4-diones of formula (I) wherein W, Q, R1, R2 and R10 are as defined in the specification and Y is COOH, wherein a corresponding C1-5 alkyl ester compound is hydrolyzed. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: Compounds of formula (I), in which [R.sup.1 and R.sup.2 ], [R.sup.3 and R.sup.4 ] and [R.sup.5 and R.sup.6 ] represent a carbon-carbon bond or two hydrogen atoms; R.sup.2 additionally represents alkyl; R.sup.7, R.sup.8 and R.sup.9 represent groups including H or OH, R.sup.10 has various significances including alkyl and alkenyl; X and Y represent groups including O and (H, OH); R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 and R.sup.23 represent H or alkyl; R.sup.20 and R.sup.21 represent groups including O, (H, OH) and (H, O-alkyl), n is 1, 2 or 3, and in addition, Y, R.sup.10 and R.sup.23, together with the carbon atoms to which they are attached, may represent a heterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, e.g. for use as immunosuppressive agents, are also described.

Abstract: There are provided compounds of formula (I), wherein R.sup.1 represents H, OH or alkoxy; R.sup.2 represents H; in addition R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; R.sup.3 represents methyl, ethyl, propyl or allyl; R.sup.4 represents H, OH, alkyl, alkoxy, halogen, amino, S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2; X represents O, (H, OH), (H, H) or .dbd.NH; and Y represents an optionally substituted cyclohexyl or substituted cyclopentyl group; with various provisos. The compounds are useful, inter alia, as immunosuppressive agents.

Abstract: Compounds of formula I, ##STR1## wherein R.sup.1 represents H, OH, protected OH or alkoxy; R.sup.2 represents H; R.sup.3 represents O or (H,OH); R.sup.4 represents methyl, ethyl, propyl or allyl; R.sup.5 represents OH, protected OH or alkoxy; R.sup.6 represents OH; R.sup.7 represents OH, alkoxy or NR.sup.8 R.sup.9 where R.sup.8 and R.sup.9 independently represent H, alkyl or aryl; in addition, R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; and R.sup.6 and R.sup.7 may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.

Abstract: There are described compounds of formula I, ##STR1## wherein R.sup.1 represents H or OH; R.sup.2 represents H; in addition, R.sup.1 and R.sup.2 may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R.sup.3 represents OH or OCH.sub.3 ; X represents O or (H,OH); and Y represents O or N--OR.sup.4, in which R.sup.4 represents H or alkyl C.sub.1-6 ; provided that when R.sup.1 is OH, R.sup.2 is H and X is O, then Y does not represent O.Processes for their production and compositions containing them, eg. for use as immunosuppressive agents, are also described.

Abstract: There are provided compounds of the general formula (1) ##STR1## (wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, a hydroxyl group or a group --OP(O) (OH) (OR.sup.4) [where R.sup.4 represents a hydrogen atom or an alkyl (optionally substituted by a hydroxyl, alkoxy, cyclic ether or cycloalkyl group), alkenyl cycloalkyl, aryl, aralkyl or aroylalkyl group], with the proviso that at least one of R.sup.1 and R.sup.2 represents a group --OP(O) (OH) (OR.sup.4); and R.sup.3 represents a hydrogen or halogen atom or a methyl group), and salts thereof. The novel compounds exhibit interesting anti-cancer activity.